Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

atomoxetine

- PMLiVE

UK’s MHRA begins rolling review of Moderna’s coronavirus vaccine

MHRA will accept and consider new evidence as it becomes available

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

- PMLiVE

It’s Brexit day – now comes the really hard stuff

Months of trade negotiations between UK and EU lie ahead

- PMLiVE

UK to add addiction warnings to opioids as use soars

Codeine-related deaths doubled in a decade

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

Time running out for ‘no-deal’ Brexit medicines laws

Needs parliament clearance before 29 March

- PMLiVE

As Brexit looms, UK medicines agency head Hudson announces departure

Search for successor must start in early 2019

Neurodiversity, ADHD and work: Obstacles and opportunities

For ADHD awareness month this year our Associate Medical Writer, Alex Teahan, has written a piece surrounding ADHD and employment. He discusses the advantages and disadvantages of ADHD at work,...

Mednet Group

- PMLiVE

MHRA cut out of regulatory work as Brexit looms

This year the regulatory body was only awarded two contracts to serve as the lead assessor on NDAs

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

- PMLiVE

MHRA: No change for pre-Brexit products after UK exits the EU

And UK plans to follow EU rules for an implementation period after March 2019

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links